



1.- Personalized Medicine
2.- Epigenetics and Networks

Alfonso Valencia

Spanish National Cancer Research Centre
CNIO

valencia@cni.es
[@alfons_valencia](https://twitter.com/alfons_valencia)

ESHG Satellite Symposium
“Machine Learning for Personalized Medicine”
Barcelona, May 2016

Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses


Siân Jones,^{1*} Xiaosong Zhang,^{1*} D. Williams Parsons,^{1,2*} Jimmy Cheng-Ho Lin,^{1*} Rebecca J. Leary,^{1*} Philipp Angenendt,^{1*} Parminder Mankoo,³ Hannah Carter,³ Hirohiko Kamiyama,⁴ Antonio Jimeno,¹ Seung-Mo Hong,⁴ Baojin Fu,⁴ Ming-Tseh Lin,⁴ Eric S. Calhoun,¹ Mihoko Kamiyama,⁴ Kimberly Walter,⁴ Tatiana Nikolskaya,⁵ Yuri Nikolsky,⁶ James Hartigan,⁷ Douglas R. Smith,⁷ Manuel Hidalgo,¹ Steven D. Leach,^{1,8} Alison P. Klein,^{1,4} Elizabeth M. Jaffee,^{1,4} Michael Goggins,^{1,4} Anirban Maitra,^{1,4} Christine Iacobuzio-Donahue,^{1,4} James R. Eshleman,^{1,4} Scott E. Kern,^{1,4} Ralph H. Hruban,^{1,4} Rachel Karchin,³ Nickolas Papadopoulos,¹ Giovanni Parmigiani,^{1,9} Bert Vogelstein,^{1,9} Victor E. Velculescu,^{1†} Kenneth W. Kinzler^{1†}



SCIENCE VOL 321 26 SEPTEMBER 2008



Manuel Hidalgo,
Director
Clinical Programme
CNIO



PALB2


Identified as breast cancer susceptibility gene whose protein is closely associated with BRCA2 and is essential for BRCA2 anchorage to nuclea structures. [2008]

PALB2 mutations have been previously reported in patients with familial breast cancer, and the PALB2 protein is a binding partner for BRCA2. [2009]

Exomic Sequencing Identifies *PALB2* as a Pancreatic Cancer Susceptibility Gene

Siân Jones,^{1,2} Ralph H. Hruban,^{2,3} Mihoko Kamiyama,³ Michael Borges,³ Xiaosong Zhang,^{1,2} D. Williams Parsons,^{1,2} Jimmy Cheng-Ho Lin,^{1,2} Emily Palmisano,² Kieran Brune,² Elizabeth M. Jaffee,^{2,3} Christine A. Iacobuzio-Donahue,^{2,3} Anirban Maitra,^{2,3} Giovanni Parmigiani,^{2,3} Scott E Kern,^{2,3} Victor E. Velculescu,¹ Kenneth W. Kinzler,¹ Bert Vogelstein,^{1,2} James R. Eshleman,^{2,3*} Michael Goggins,^{2,3,4*} Alison P. Klein^{2,3**†}


www.sciencemag.org SCIENCE VOL 324 10 APRIL 2009



Spotlight on Clinical Response

Personalizing Cancer Treatment in the Age of Global Genomic Analyses: *PALB2* Gene Mutations and the Response to DNA Damaging Agents in Pancreatic Cancer

Maria C. Villarroel^{1,2}, N.V. Rajeshkumar^{1,2}, Ignacio Garrido-Laguna^{1,2}, Ana De Jesus-Acosta^{1,2}, Siân Jones^{1,2}, Anirban Maitra^{1,2}, Ralph H. Hruban^{1,2}, James R. Eshleman^{1,2}, Alison Klein^{1,2}, Daniel Laheru^{1,2}, Ross Donehower^{1,2}, and Manuel Hidalgo^{1,2}



EL PAÍS.COM | Salud

Lunes, 21/3/2011, 08:22 h

Inicio Internacional España Deportes Economía Tecnología Cultura Gente y TV Sociedad Opinión Blogs In English buscar

Educación | Salud | Ciencia | El Viajero | El País semanal | Domingo

ELPAIS.COM > Sociedad > Salud

Un cáncer de páncreas curado gracias al trasplante a un ratón

Transferir el tumor al animal permite investigar con los fármacos y dar con una solución personalizada - Un médico español lidera esta técnica

D. ALANDETE / E. DE BENTO - Washington / Madrid - 11/01/2011

Vota ☆☆☆☆☆ | Resultado ★★★★★ 161 votos

Comentarios - 22

Twitter 32

Recommend 38

Los sufridos ratones de laboratorio pueden ser los futuros catavenenos de los enfermos de cáncer. Al menos, eso es lo que está investigando uno de los recientes fichajes del Centro Nacional de Investigaciones Oncológicas (CNIO), Manuel Hidalgo. El médico, que hasta hace poco estaba en el Johns Hopkins de Baltimore (EE UU), ha conseguido con la ayuda de estos roedores lo que él cree que se podría calificar como "el primer caso de un cáncer avanzado de páncreas que se ha curado".

Importación de cerebros

Adoptar hábitos de vida saludables ayudaría a evitar el 40% de los cánceres

La noticia en otros webs

- webs en español
- en otros idiomas

El sistema que se aplicó -de momento a un único paciente- es una combinación de análisis genético para saber qué fármacos pueden funcionar y de experimentación directa sobre el propio tumor. "Tuvimos suerte y acertamos, porque no había margen de error".

Los ratones desempeñaron un papel relevante: se le trasplantó el tumor que se había quitado al paciente, y así se pudo ensayar en él qué fármaco funcionaba, sin que tuviera que exponerse a



Mark Gregoire (en el centro) rodeado de su familia después de superar el cáncer de páncreas.


CNIO co-clinical cancer initiative



Manuel Hidalgo,
Director
Clinical Programme
CNIO



**Clinical
Trial**



Genomic alterations

N#	PATIENT ID	TUMOR TYPE	N# MUTS	RELEVANT MUTATED GENES	N# CNV	RELEVANT CNV	PUTATIVE TARGETS
1	PGDX4	Neuroendocrine tumor	5	CREB3L3, ITPR2, MYO5B	0	0	CREB3L3
2	PGDX30	Glioblastoma	63	EPHA3, NF1, PTPN11, FAS, CDKN2A	0	0	NF1
3	PGDX7	High grade pancreatic neuroendocrine tumor	62	ARID1A, ARID1B, JAKMIP2, JARID2, PIK3C2A, PIK3CA, SSTR2, DDR2, TP53	6	GNG11	PI3KCA, DDR2
4	PGDX11	Pancreatic Adenocarcinoma	38	KRAS, UBA1, FAM83H, SMAD4, SLC15A2, PNWIL3, SLC3A2, SLC22A17, TP53.	10	0	None
5	PGDX61	Melanoma Uveal	5	GNA11, TAOK3	0	0	GNA11
6	PGDX68	Colon cancer	71	APC, DICER 1, TP53, CHEK1, SOS1	63	0	CHEK1
7	PGDX76	Melanoma	952	BRCA1, EZH2, FGFR2, FN1, IGF1R, KDR, KRAS, MET, MPL, PRKCB, PIK3C2G, PTK2B.	0	0	FGFR2, IGF1R, PIK3C2G, MET, BRCA1
8	PGDX135	Melanoma	29	BAI3, DNAHS, MDN1, NRAS	2	SKT19	NRAS
9	PGDX368	Pancreatic Adenocarcinoma	18	SMAD4, KRAS, ERBB2IP	0	0	ERBB2IP
10	PGDX331	Pancreatic Adenocarcinoma	21	KRAS, XPC, P53	0	0	XPC
11	PGDX369	Pancreatic Adenocarcinoma	29	KRAS, P53, SMAD4	3	0	None
12	PGDX379T2	Renal Carcinoma	25	BAP1	965	ZAP70, FGFR3, NOTCH1, TERT, STK11, GNA11, ZNF668, SOCS1, IRS2	BAP1, FGFR3, NOTCH1, STK11, GNA11.
13	PGDX330	Glioblastoma	64	MLLT10, PBRM1	27	EGFR, CDKN2A, ERF1	EGFR
14	PGDX27	NSCLC	45	EGFR, EZH2, TPR, TP53, RHOH	0	0	EGFR
15	PGDX17	NSCLC	69	ARID4B, PIK3R6, PTPRC, TP53, TOPO2A	13	0	PTPRC, KIF5B-RET Fusion, STK11 Whole Gene Deletion
16	PGDX140	NSCLC	391	BUB1B, CYLD, EPHB6, EGFR, KRAS, KEAP1, MSH6, NTRK1, NTRK3, MUTYH, RUNX1T1, TP53	12	CDKN2A	EGFR
17	PGDX24	SCLC	32	PAPPA2	Not Done	Not Done	None
18	PGDX60	NSCLC	9	NOCTH2, MML3	6	0	NOCTH2
19	PGDX3	NSCLC	38	DLK1, JAK3	Not Done	Not Done	JAK3
20	PGDX48	Duodenal cancer	127	CARD11, CHL1, FANCD2, IRS1, NRAS, SMARCA4, TP53, PIK3R1	25	0	NRAS, PIK3R1
21	PGDX39	Colon cancer	172	APC, EGFR, FN1, GRM1, TP53, TSC2	0	0	EGFR, FN1, TSC2
22	PGDX327	Colon cancer	108	APC, AXIN2, EGFR, KDM6A, PTEN, PI3KCA, TP53	32	RECQL4	EGFR, PI3KCA, PTEN
23	PGDX310	Esophageal cancer	96	PIK3R1, NF1, TP53	65	CCND1	NF1, PIK3R1

Garralda et al.

Integrated Next Generation Sequencing and Avatar Mouse Models for Personalized Cancer Treatment.

Clinical Cancer Research 2014

Case 3: High grade pancreatic neuroendocrine tumor

- 44 years old male.
- High grade neuroendocrine carcinoma with disseminated lymph node disease
- Prior treatment with gemcitabine-Oxaliplatin: PR (Partial Response).
- When Progression Disease (PD): Fresh tumor specimen from lymph node was obtained for exome sequencing and for Avatar/xenograft generation.

Exome sequencing analysis:
- 64 somatic relevant mutations
- 6 Copy number variations

Point mutation in *PIK3CA* gene: 909F>C

PI3K inhibitors and MEK inhibitors


Point mutation in DDR2 protein: 381P>A

DDR2 mut - 4% of Squamous Cell Lung Cancer. DDR2 mut associated with sensitive to Dasatinib (*Hammerman et al. Cancer Discovery 2011:*)


Case 3: High grade pancreatic neuroendocrine tumor

Avatar PDX- Panc 1 test

PI3Ki, MEKi and Gemcitabine



Dasatinib + Gemcitabine



Mutation in PI3K

Patient's
treatment


Mutation in DDR2

Why it did not work?

CNIO co-clinical cancer initiative





Manuel Hidalgo,
Director
Clinical Programme
CNIO





Pancreas PDXs conserve key features of their tissue of origin

A)



B)









Daniel Rico



Raquel Martinez


**Martinez-Garcia et al.,
Genome Med 2014**



Pancreas PDXs conserve key features of their tissue of origin

*Martinez-Garcia et al.,
Genome Med 2014*

CNIO co-clinical cancer initiative





CREDIT: Amparo Garrido/CNIO/Fátima Al-Shahrour
Fátima Al-Shahrour

Search Articles

Advanced Search

Search

Special Issue

Applying Bioinformatics to Precision Medicine

A new breed of scientist

According to Valencia, the job that Al-Shahrour does requires a very wide range of knowledge and skills; he emphasizes her "biological background, capacity to develop bioinformatics methods, deep understanding of genomics, good communication skills and proved record in team management." Also important, he adds, is her clear understanding of the limitations of the experimental and computational techniques.

Early-career scientists who wish to follow in her footsteps must be ready to embrace the training challenges.

Tamayo writes: "My advice to them is to study mathematics (not only old statistics but also advanced probability), information theory, machine learning, programming, numerical methods, chemistry, physics, cellular biology and biochemistry. It is important not only to be able to talk to multiple domain experts, and develop a solid hard-core analytical mind frame to cast problems, but also to have access to a rich set of paradigms about how to deal with complexity." Cancer pharmacogenomics is "a particularly demanding field that requires a lot of flexibility and adaptability in terms of what problems one solves over time and in requiring to learn from many fields of expertise," he adds.

CNIO personalized Medicine Initiative

- Workflow of PerMed
 - Constant flow of cases
 - Short response time (days)
 - Weekly meeting with clinicians
 - Accumulating statistics to derive patterns
- *still ... this is a research project (all PerMed are research projects)*

CNIO co-clinical cancer initiative



Mards Genome Medicine 2010, 2:84
<http://genomemedicine.com/content/2/1/84>



MUSINGS

The \$1,000 genome, the \$100,000 analysis?

Elaine R Mards*

Clinical Genetics Has a Big Problem That's Affecting People's Lives




Unreliable research can lead families to make health decisions they might regret.

[Daniel MacArthur](#) at Massachusetts General Hospital found a similar trend in [a study of over 60,000 people](#), the results of which have been uploaded to a pre-print server. On average, each of these volunteers is walking around with 53 gene variants that are classified as “pathogenic” in two widely-used databases. When the team took a closer look at 200 of these variants, they found enough evidence to classify just *nine* of them as pathogenic.


“Reproducibility problems in clinical genetics ... have massive and real-time consequences for thousands of families.”

Bioinformatics for personalize medicine





Genome Analysis




Consequences of alterations: SNPs, CNVs, miRNA, Epigenetics



Phenotypic and pathways Analysis



Drug relation Proteins, genes pathways



Valencia and Hidalgo *Genome Medicine* 2012, 4:61
<http://genomemedicine.com/content/4/7/61>



REVIEW

Getting personalized cancer genome analysis into the clinic: the challenges in bioinformatics

Alfonso Valencia* and Manuel Hidalgo



Alternative Splicing

In allowing for the generation of a diverse range of mature RNAs from the same gene, alternative splicing allows has considerable theoretical potential to expand the range of cellular proteins.


Recent studies estimate that 40–80% of multi-exon human genes can produce differently spliced mRNAs.

There are many studies that implicate alternative transcripts in biological processes such as development.

This has lead to the hypothesis that alternative splicing can explain the apparent lack of correlation between organism complexity and numbers of genes.

*In the past few years, it has become clear that a phenomenon called alternative splicing is one reason human genomes can produce such complexity with so few genes.**

*Science, July 2005





APPRIS - principal functional isoforms



<http://appris.bioinfo.cnio.es/>

APPRIS Schema

The UniProt database picks one variant and clusters the others around it.

The APPRIS database select **principal isoforms based on:**

- protein structural information,
- functionally important residues,
- protein functional domains and
- evidence of cross- species conservation.



Assumption 1: genes *have just one principal isoform*

Assumption 2: the principal isoform is the *oldest in evolutionary terms.*


APPRIS: annotation of principal and alternative splice isoforms.

Rodriguez JM et al. Nucleic Acids Res. 2013, 2015

Tress ML et al. Bioinformatics. 2008


by Michael Tress

2 or more protein isoforms for 0.67% of the human genome



(ketohexokinase homologous replaceable exons).

Isoforms with small differences are significantly over-represented



GENETICS

Isoform Identification

The differential reconnection of transcribed exons, termed alternative splicing, has the potential to result in one gene encoding multiple protein isoforms. The degree to which alternatively spliced transcripts are translated into functional proteins, however, is not well understood. Ezkurdia *et al.* used data across multiple mass spectrometry experiments to investigate the degree to which genes with alternative transcripts gave rise to protein isoforms. Comparison of the predicted proteins from the gene and genetic variant database of ENCODE (GENCODE) to the Swiss-Prot database allowed for the identification of 150 human genes that encoded at least one protein isoform and 13 with three or more, with the caveat that identification was biased toward those most likely to be detected. Heterogeneous nuclear ribonucleoproteins, which are involved in the regulation of alternative splicing, showed enrichment in alternative isoforms. Furthermore, the majority of differences detected among all predicted isoforms differed in sequence by the insertion/deletion of a single amino acid. Investigation into the *Drosophila* and mouse proteomes revealed similar patterns. Together, these results suggest that alternative splicing is under selective constraint. — LMZ

Science

Mol. Biol. Evol. **29**, 10.1093/molbev/mss100 (2012)

MBE Advance Access published April 17, 2012

Comparative Proteomics Reveals a Significant Bias Toward Alternative Protein Isoforms with Conserved Structure and Function

lakes Ezkurdia,^{†1} Angela del Pozo,^{†1} Adam Frankish,² Jose Manuel Rodriguez,¹ Jennifer Harrow,² Keith Ashman,³ Alfonso Valencia,^{*1} and Michael L. Tress^{*1}

Michael Tress



Staff Scientist

National Center for Cancer Research (CNIO)

2006 – Present (7 years)

Research on protein structure prediction, protein function, and alternative splicing.

Post-Doctoral Researcher

CNB

March 2002 – April 2006 (4 years 2 months)

Researcher in bioinformatics/computational biology



Education

University of Warwick

1997 – 2001

University of York

MSc, Biological Computation

1989 – 1990

Bath Spa University

BSc, Biochemistry




1983 – 1987

A single isoform (principal isoform) per gene

Alterations in isoform composition in cancer

More than anticipated trans-splicing events

Chimeras confirmed at the RNA and protein levels



D
 Chimeric Protein Sequence (Part.): ...SRRRNTPRPPSTATMVTG RDFPADFFERDAKD...
 Junction: MVTG RDFP
 Found Peptide: SRRRNTPRPPSTATMVTG RDFPADFFERDAKD



Chimera of **actin**, ACTG1 and **ribosomal protein RPL13A**




Overlapping unique peptides from 18 mass spectrometry experiments (Pvalue<10⁻⁵²) confirming transcript from ChimerDB (Kim et al., 2006, Kim et al. 2010) and a few further confirmed by SRM

The motif 'GDGV' (a red rectangle) is the ATP-binding site missing in the chimera


Chimeric protein production

Chimeric transcripts arise from the joining of exons from two or more different genes. Reporting of such transcripts has become more widespread as data from genome-wide transcriptional analyses has increased. However, the number of known chimeric transcripts far outnumbers the reported number of chimeric proteins. Here, Frenkel-Morgenstern et al increase the number of identified translated chimeric transcripts and describe features indicative of their biological functionality. Firstly the authors analysed previously reported human tissue RNA-seq datasets for the presence of chimeric reads, that is, those that do not align to annotated transcripts and include a chimeric exon-exon junction. This approach confirmed the expression of 175 out of 7,424 previously reported chimeric transcripts from 16 human tissues. Analysis of the level of expression of these transcripts revealed that while chimeric transcripts are themselves expressed at a low level, they incorporate transcripts that are normally expressed at a high level; they are also expressed in a highly tissue-specific manner. To confirm the translation of these transcripts, the authors both searched mass spectrometry databases and generated their own shotgun mass spectrometry datasets. They initially searched for peptides that spanned a junction site of the human chimeric transcripts and they found 12 chimeric proteins. Following this, they generated targeted mass spectrometry data and this confirmed the expression of a further three novel chimeric proteins. The 175 expressed chimeras are enriched in signal and transmembrane peptides suggesting that generating chimeric transcripts


is a mechanism for altering the localisation of the translated protein. Thus the authors' data suggests a potential function for chimeric proteins. The search is on to elucidate precise biological roles.



Caption



Transplicing/ chimeric mRNAs



Research

Chimeras taking shape: Potential functions of proteins encoded by chimeric RNA transcripts

Milana Frenkel-Morgenstern,¹ Vincent Lacroix,² lakes Ezkurdia,¹ Yishai Levin,³ Alexandra Gabashvili,³ Jaime Prilusky,⁴ Angela del Pozo,¹ Michael Tress,¹ Rory Johnson,⁵ Roderic Guigo,⁵ and Alfonso Valencia^{1,6}

Genome Research
www.genome.org

Two overlapping mass-spec peptides, (18 experiments, Pvalue<10-7, FDR<1%)
Dr. Levin, Weizmann Institute

ChiTaRS: chimeric transcripts/proteins Database



ChiTaRS
THE DATABASE OF CHIMERIC TRANSCRIPTS AND RNA-SEQ DATA

HOME FULL COLLECTION & SEARCH DNA SEARCH BREAKPOINTS LINKS DOWNLOADS HELP

SEARCH CHIMERA COLLECTION

You can use special characters (* > <) for the search by Keyword, Tissue, Gene Name, Identity

Search Name: SEARCH

Choose parameters to search by: Chimera Full Collection Keyword Gene Synonym Tissue Name Identity Search Name Chimera Full Collection ChimeraID

Rank: Junction Consistency: RNAseq evidence Breakpoints Mass-spec Hits


Organisms: Homo Sapiens Mus musculus D. Melanogaster

RESULT FOR THE SEARCH: CHIMERA FULL COLLECTION:

Total sequences: 16188

[1] 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 ... 16 >>

Organism	Graphical View	Sequence [#]	First Gene (1)			Second Gene (2)			Deviation		Rank	RNAseq and/or Mass-spec evidences	Cancer Breakpoint, Pubmed Reference		
			Name ₁	Start ₁	End ₁	Ident ₁ %	Name ₂	Start ₂	End ₂	Ident ₂ %				Eloc (x)	Sloc (y)
Homo Sapiens	SplGraphs	AA16883 [5]	CARD10	1	217	99.6	CAMK2N1	211	496	100.0	0	0	0	NA	
Homo Sapiens	SplGraphs	EF632110 [2]	HNRNPA2B1	1	175	100.0	ETV1	174	417	100.0	0	0	0	NA	more info
Homo Sapiens	SplGraphs	DA134735 [1]	ZMYM2	1	193	99.5	RAB1A	194	551	100.0	0	0	1	NA	open: 1767156 185942
Homo Sapiens	SplGraphs	EF428111 [1]	PRKAR1A	1	182	100.0	RAR							Human lung total RNA, lot 0904002 causasia organ = ovary frame = 3 protseq = KTPPFDFLFK	
Homo Sapiens	SplGraphs	DA092511 [1]	CHL1	1	272	99.7	ELAVL1							Number of Reads = 4 Number of Distinct Reads = 2 Number of OT Issues = 3 Number of Reads in Best Tissue = 2 Number of Distinct Reads in Best Tissue = 1 Tissue Specificity = 1.039720 RPKM = 0.026422	
Homo Sapiens	SplGraphs	BG978110 [2]	GSTP1	27	204	95.5	PSMB1	205	459	98.9	0	0	0	HS440	
Homo Sapiens	SplGraphs	AJ438986 [1]	NUP98	1	737	100.0	HOXC13	734	992	100.0	0	0	0	NA	from dbCRID: aberration = t(11;12)(p15;q13) location1 = p15 location2 = q13



Research

Chimeras taking shape: Potential functions of proteins encoded by chimeric RNA transcripts


Milana Frenkel-Morgenstern,¹ Vincent Lacroix,² Iakes Ezkurdia,¹ Yishai Levin,³ Alexandra Gabashvili,³ Jaime Prilusky,⁴ Angela del Pozo,¹ Michael Tress,¹ Rory Johnson,⁵ Roderic Guigo,⁵ and Alfonso Valencia^{1,6}

Genome Research
www.genome.org




Milana Frenkel-Morgenstern et al., NAR 2013. 2015

Technical Infrastructure



Enables Execution of pipelines




Operation at file system level
Developed CNIO, accessible github, will be installed at CNAG.



as in ICGC
(similar to MongoDB)



as in ICGC frontend



Use cases are divided in:

1. Data management
2. Answer research questions

The data portal provides functionalities to satisfy both categories.


Bioinformatics Core Unit



Gonzalo Gómez



Osvaldo Graña



Miriam Rubio



David G. Pisano

Spanish National Bioinformatics Institute

Victor de la Torre



Miguel Vazquez



**José María
Fernández-González**





A Network Biology Approach to Information Processing in Epigenetic Regulation

Alfonso Valencia

Spanish National Cancer Research Centre
CNIO



valencia@cni.es
@alfons_valencia

**ESHG symposium 2016: Machine Learning
for Personalized Medicine**

Barna May 2016


EPIGENETICS/EPIGENOMICS

Complex relationship between Cytosine modifications, Histone marks and Chromatin Binding Proteins



Stem cells

Nat Rev Genet. 2012 May 29;13(7):484-92



Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1

Mamta Tahiliani¹, Kian Peng Koh¹, Yinghua Shen², William A. Pastor¹, Hozefa Bandukwala¹, Yevgeny Brudno², Suneet Agarwal³, Lakshminarayan M. Iyer⁴, David R. Liu², L. Aravind⁴, and Anjana Rao^{1,2}
Science. 2009 May 15; 324(5929): 930-935. doi:10.1126/science.1170116.

The Nuclear DNA Base 5-Hydroxymethylcytosine Is Present in Purkinje Neurons and the Brain
 Skirmantas Kraucionis and Nathaniel Heintz
Science 324, 929 (2009);
 DOI: 10.1126/science.1169786



Segmenting the Genome in Functional Regions

Mouse embryonic stem cells
“Core” epigenomic features (basic scaffold)

Histone modifications

H3K4me3 --- ENCODE, GSE11724, GSE12241, GSE36114

H3K4me2 --- ENCODE, GSE11172, GSE36114

H3K4me1 --- ENCODE, GSE11172, GSE36114

H3K27Ac ---- ENCODE, GSE36114,

H3K9me3 --- ENCODE, GSE12241, GSE18371

H2Aub1 --- GSE34518

H3K27me3 --- GSE12241, GSE41589, GSE36114

H3K36me2 --- GSE41589

H3K36me3 --- ENCODE, GSE11724, GSE12241, GSE34518, GSE41589, GSE36114

H3K79me2 --- GSE11724

H4K20me3 --- GSE12241

H3K9Ac --- ENCODE

H2AZ --- GSE36114

Cytosine modifications

5mC --- GSE28682


5hmC --- GSE28682

5fC --- GSE40148


Insulator

CTCF --- GSE11431, GSE25777, GSE28247

17 "Core" epigenomic features
CTCF, cytosine & histone modifications



20 Chromatin states
Combinations of core features



20 Chromatin states
obtained by
combining
ChIPSeq data
of 17 core
features

ChromHMM

B

C

D

Chromatin Related Proteins (data from mouse ESCs)

Polycomb

CoREST --- GSE27841

REST --- GSE27841

RING1B --- GSE34518, GSE42466

SIN3A --- GSE24843

SUZ12 --- GSE11724, GSE42466, 41589, 11431

PHF19 --- GSE41589, GSE41609

ESC Transcription factors

C-MYC --- GSE11431

E2F1 --- GSE11431

MAX --- GSE48175

NANOG --- GSE11431, GSE11724

N-MYC --- GSE11431

OCT4 --- GSE11431, GSE11724

SMAD1 --- GSE11431

SOX2 --- GSE11431, GSE11724

STAT3 --- GSE11431

KLF4 --- GSE11431

Tcfcp2l1 --- GSE11431

Enhancer

P300 --- GSE11431, GSE28247

Cohesin complex

NIPBL --- GSE22562

SMC1 --- GSE22562

SMC3 --- GSE22562

RAD21 --- GSE25777

Others

CBX3 --- GSE4424

CBX7 --- GSE42466

HCFC1 --- ENCODE

MAFK --- ENCODE

ZC3H11A --- ENCODE

ZNF384 --- ENCODE

ESRRB --- GSE11431

KAP1 --- GSE41903

LAMINB --- GSE28247

MI2B --- GSE27841

OGT --- GSE39154

TCF3 --- GSE11724

BRG1 --- GSE14344

Chromatin remodelers

HDAC1 --- GSE27841

HDAC2 --- GSE27841

KDM2A --- GSE40860

KDM2B --- GSE40860

LSD1 --- GSE18515, GSE27841

TET1 --- GSE24843

MBD1A --- GSE39610

MBD1B --- GSE39610

MBD2A --- GSE39610

MBD2T --- GSE39610

MBD3A --- GSE39610

MBD4 --- GSE39610

MECP2 --- GSE39610

MLL2 --- GSE48172

SETDB1 --- GSE18371

Transcription related

POLII --- GSE12241, GSE28247

RNAPII-8WG16 --- GSE34518

RNAPII-S2P --- GSE34518

RNAPII-S5P --- GSE34518

RNAPII-S7P --- GSE34518

MED12 --- GSE22562


MED1 --- GSE22562

TAF1 --- GSE36114

Epigenomic Mouse Stem Cell co-localization Network

60 Chromatin-related Proteins (CrPs)

Core epigenomic features



Distribution of CRPs / Epi features in 20 Heterochromatin states




Heterochromatin state dependent Co-localization Networks

Epigenomic Mouse Stem Cell co-localization Network

60 Chromatin-related Proteins (CrPs)


Core epigenomic features





Distribution of CRPs in 20 Heterochromatin states



Heterochromatin state dependent Co-localization Networks



Inference of chromatin **DIRECT** co-localization networks from ChIP-seq data



Co-localization Correlation network
With **positive** interactions and
mutual exclusion (**negative**) interactions

Sparse Partial Correlation Networks
(Lasserre et al. 2013)

Regularized linear regression with Elastic Nets
(Perner et al. 2014)



MAX-PLANCK-GESellschaft



**Juliane
Perner**




**Martin
Vingron**




**Ho-Ryun
Chung**

State 18 (Polycomb promoter)




Colors reflect known protein complexes


Global Co-localization network reflects organization in protein complexes



Epigenetics as a communication system



From “Location” to “Communication” Network



Sender

- 1.-Writer/Eraser from experiments
- 2.-Influences signal location (eg. KOs)

Signal


Histone marks (H3K4me1, ...).
Cytosine modifications (5mC, 5hmC, 5fC).

Receiver

Not-sender signal interactors


KNOWLEDGE FROM THE LITERATURE -> EDGE DIRECTIONALITY

124 (52.5%) directional interactions: 56 emitter / signal, 68 receiver/signal
18 CrP nodes act as emitters or receivers of different signals




- COMPLEXES**
- SOX2/OCT4
 - Polycomb
 - CoREST/REST
 - POL II
 - No complex assign
 - Mediator
 - TET1/SIN3A
 - Mi-2/NuRD
 - Cohesin

Indegree (Transcription)




Outdegree

(5hmC is the message with more receivers)



Co-localization network



Indegree (Transcription, 5hmc)



Outdegree
(5hmC is the message with more receivers)

Betweenness/Centrality
control that this node exerts over the interactions of other nodes in the network

5hmC is the most central node

$$C_b(n) = \sum_{s \neq n \neq t} (\sigma_{st}(n) / \sigma_{st})$$


Influence/popularity



- **Influential nodes:** information easily spreads out to the rest of the network,
- **Popular nodes** gather information from many regions of the network.

Effect of directionality miss-assignments and random edges removal


chromnets




star-like chromnets: communication modules that connect different protein complexes (emitter/signal and signal/receiver interactions)

i.e. two central connectors (5fC and RYBP) connecting Polycomb, Mediator and TET1-SIN3A complexes >>> enriched in active transcription states and regulatory elements.

5hmC nucleates a star like sub-network



overall enrichment of the chromatin states



5hmC indirectly connects to H3K4me1 via TET1, and with 5mC via MBD2T.

Chromnet is enriched in regulatory elements.





Figure 1

Co-evolution and evolutionary interactions



Darwin (1859), *On the origin of species*.

Anderson et al. *American Journal of Botany*. (2005)

Co-evolution:

- ***Reciprocal evolution between interacting species driven by natural selection (John N. Thompson).***
- ***Co-evolution in about biological objects speaking evolution with each other.***
- ***Evolution of communication requires co-adaptation of the agents and adaptation of the interaction as whole (Maynard Smith, J. & Harper, D.G.C. 2003)***

Mirrortree Method: finding interaction partners at genome level

High-confidence prediction of global interactomes based on genome-wide coevolutionary networks


David Juan ^{*}, Florencio Pazos [†], and Alfonso Valenc

+ Author Affiliations

Proc Natl Acad Sci U S A. 2008


Proce

David Juan, Florencio Pazos
Nat. Rev Genet 2013



Detecting co-evolving CrPs

13,579 metazoan (88 species) trees from eggNOG (1)



(2,3)



19,267 orthologs-only trees containing mouse proteins

58 CrPs

10,000 x 58 random proteins
(background distribution)

p value < 0.05

Maximum-entropy distribution in the space of species-species distance bins $\{d\}$ for fixed single and pair protein frequencies



$$P(d) = \exp \left[\sum_a h_a(d_a) + \sum_{a,b} J_{a,b}(d_a, d_b) \right] \quad (4)$$

$J_{p,q}$ regulates the interactions between proteins in the model.
A strong positive parameter can be interpreted as the direct symmetrical interaction between the two proteins a, b


1.-Powell, S. *et al. Nucleic Acids Res.* **42**, D231–239 (2014).

2. Ruan, J. *et al. Nucleic Acids Res.* **36**, D735–D740 (2008).

3.-Juan, D., Rico, D., Marques-Bonet, T., Fernández-Capetillo, O. & Valencia, A.. *Biol. Open* **2**, 1402–1411 (2013).


4.-Schneidman E, *et al.* (2006). Nature 440: 1007–1012 Weak pairwise correlations imply strongly correlated network states in a neural population

Getting a direct co-evolutionary network




coevolutionary couplings network

$$P(d) = \exp \left[\sum_a h_a(d_a) + \sum_{a,b} J_{a,b}(d_a, d_b) \right]$$



Direct \longleftrightarrow + indirect \longleftrightarrow

34 Co-evolution based connections of the 58 CrPs



David Juan





Simone Marsili

About metazoan co-evolution (5hmC is key in communication and co-evolution)

32% of co-evolving pairs co-localize in mESCs

$P < 1E-5$




About metazoan co-evolution


(5hmC is key in communication and co-evolution)

32% of co-evolving pairs co-localize in mESCs $P < 1E-5$


Co-evolution points to Sender-Receiver
epigenetic communication




Co-evolution points to **5hmC**-mediated
epigenetic communication




Co-evolution between 5hmC interactors






5hmC key in communication & co-evolution in mESC

ChIP-Seq data



Sparse partial correlation
+
Elastic Networks

Genome Wide Localization Network




Phylogenetic trees



Pairwise maximum-entropy
model based on tree similarities

Co-evolution Network



Co-evolution

*Evolution of
communication
requires co-adaptation
of the agents and
adaptation of the
interaction as whole*
**(Maynard Smith, J. &
Harper, D.G.C. 2003)**

Sender → Message → Receiver



mESC Epigenetic Network (part 1)


Chip-Seq data – co-localization – biological complexes

Chromatin related proteins biological functions and chromatin states

5hmC, stem cells and development

Co-Evolution of Chromatin related molecular complexes


**A network approach
integrates 3D contacts with
epigenomic data
(part 2)**



Vera Pancaldi
Structural and Computational Biology Group
Spanish National Cancer Research Centre (CNIO)

17 May 2016
EMBL-EBI, Hinxton


The 3D structure of chromatin



Ea et al. **Contribution of Topological Domains and Loop Formation to 3D Chromatin Organization.** *Genes* 2015
 Z. Duan, ... W Stafford Noble, **A three-dimensional model of the yeast genome,** *Nature* 2010

Chromatin Interaction Networks (CINs)

Unravelling 3D chromatin contacts
Chromosome Conformation Capture methods




ChIA-PET
Genome-wide
Requires pull-down of specific protein (enriches for interactions mediated by it)

3C, 4C, 5C
Local
no pull-downs

HiC Genome wide
No pull-downs

Construct networks where:
Node = chromatin fragment Edges=contacts in 3D

Montavon and Denis Duboule, **Landscapes and archipelagos: spatial organization of gene regulation in vertebrates**, Trends in Bio 2012; KS Sandhu, Y Ruan, **Large-scale functional organization of long-range chromatin interaction networks**. Cell Rep 2012




n=1173

What about genes? PCHi-C!

Problem so far: HiC contact maps dominated by interactions far from genes.
Need very high coverage to pick promoters

Solution: Promoter-Capture HiC (PCHiC)
Add promoter capture step
Obtain promoter-centred contact maps
(No pull-downs, genome-wide)

It allows to look for transcription factories
(Multiple genes transcribed together)



Copyright © 2005 Nature Publishing Group
Nature Reviews | Genetics

Lyubomira Chakalova¹, ... Peter Fraser **Replication and transcription: Shaping the landscape of the genome**
Nat Rev Gen 2005; Schoenfelder, S. *et al.* **The pluripotent regulatory circuitry connecting promoters to their long-range interacting elements.** Genome Res. 2015.


PChI-C networks in mESCs

Interactions involving at least 1 promoter

Statistics:
Chromatin fragments (4Kb)
55,845 nodes
(19425 promoters)
69,987 edges
1 major connected component

20,523
Edges connecting
Two promoters

Coloured by modules
(highly interconnected
Portions of the network)



Data processing with CHiCAGO
(Mikhail Spivakov)

PChI-C networks in mESCs

Interactions involving at least 1 promoter


Statistics:
Chromatin fragments (4Kb)
55,845 nodes
(19425 promoters)
69,987 edges
1 major connected component

20,523
Edges connecting
Two promoters


Coloured by modules
(highly interconnected
Portions of the network)

Data processing with CHiCAGO
(Mikhail Spivakov)

EZH2 Peaks in chromatin fragments



Chromatin Assortativity (ChAs)



Approach:

For each chromatin fragment (node):

Calculate abundance of epigenetic feature



Eg: Proportion of fragment that has peak of EZH2 ChIP-seq

Average of proportion throughout the network (rare 0.02)

For each epigenetic feature, calculate Assortativity on the network

Eg: How much more likely are fragments covered by EZH2 peaks to interact with each other?

(high 0.33)




Data:
PChIc networks in mouse Embryonic Stems Cells (mESCs)
 (Collaboration with Peter Fraser, Babraham Institute)

78 epigenetic features (3 cytosine modification, 13 histone modifications, chromatin related proteins binding peaks)

Epigenomic Co-localization and Co-evolution Reveal a Key Role for 5hmC as a Communication Hub in the Chromatin Network of ESCs, Juan et al. Cell Reports 2016

PCG is highly assortative in PChi-C networks

- PolyCombGroup (PCG)
- Proteins and marks
- EZH2
- RING1b
- SUZ12
- PHF19
- H3K27me3
- H2Aub1
- RNA Polymerase 2



Polycomb represses and constrains the network

Cell Stem Cell
All Content
 Cell Stem Cell All

Explore Online Now Current Issue Archive Journal Information For Authors

Stefan Schoenfelder, Robert Armstrong, Borbala Mifsud, Mayra Furlan-Magaril, Anna Kristina Tabbada, Simon A Haruhiko Koseki, Peter Fra

[Affiliations](#) | [Contributions](#)

Nature Genetics (2015) | doi:10.1038/ng.3411
 Received 10 December 2015

[< Previous Article](#)

Volume 17, Issue 6, p748–757, 3 December 2015

Short Article

[Switch to Standard View](#)


Dynamic Reorganization of Extremely Long-Range Promoter-Promoter Interactions between Two States of Pluripotency

Onkar Joshi⁵, Shuang-Yin Wang⁵, Tatyana Kuznetsova, Yaser Atlasi, Tianran Peng, Pierre J. Fabre, Ehsan Habibi, Jani Shaik, Sadia Saeed⁶, Lusy Handoko⁷, Todd Richmond, Mikhail Spivakov, Daniel Burgess, Hendrik G. Stunnenberg

Chromatin Assortativity in different subnetworks

In P-O subnetwork features that are only on promoter fragments have ChAs <0

HCFC1 (transcription activator complex),
SIN3A (transcriptional repressor complex), KDM2A (H3K26 demethylase),
NMYC, OGT (histone acetyl transferase. complex), H3K4me2



Comparing P-P and P-O


Identify features that have different assortativities in P-P and P-O contacts

PCG on diagonal
 Similar ChAs > 0 in P-P and P-O
 Equal importance

RNAPII:
 Variable ChAs in P-O,
 ChAs > 0 in P-P



H3K4me3: Mark associated to
 active promoters
 ChAs > 0 in P-P
 ChAs < 0 in P-O
 (only present in promoters)

Fragments that have this mark
 are more likely to interact
 Preferential contacts of active
 gene promoters.



Assortativity of RNA Polymerase 2

5 Different RNAPII features
 Binding peaks for different RNAPII variants



ChAs of RNAPII in P-O variable

Non-elongating RNAPII has low ChAs in P-P


Is expression enhancing mediated by RNAPII S2p?

Assortativity of RNAPII forms in
 Interactions of promoter and enhancers

Active enhancer
 H3K4me1+H3K27ac


Poised Enhancer
 H3K4me1+ H3K27me3

Non-enhancer
 No H3k4me1




Topological properties of PCG and RNAPII nodes

Apply Moduland to identify overlapping chromatin communities, measure bridgeness





LCC= Large connected component




	Bridgeness	Betweenness centrality	Degree	Clustering Coefficient
PCG	Low	High	High	Very low
RNAPII general	High	Low	Low	Low
RNAPII S2p	Low	Very low	Very low	Medium

Model proposed:




Experimental results on RNAPII S2p

Whereas RNAPII S5P accumulates in transcription factories, RNAPII S2p stays peripheral



A model of transcription; gene promoters are loaded with RNAPII-Ser5P (Ser5 light gray) in factories. Elongating RNAPII-Ser2P (Ser2, dark gray) moves to the adjacent nuclear space when it becomes phosphorylated at Ser2 by CDK9


Epigenomic Mouse Stem Cell



Distribution of CRPs in 20 Heterochromatin states


Part 1

A Epigenetic + coevolutionary network



Part 2

Cromatin Capture Network



Copyright © 2015 Nature Publishing Group
Nature Reviews | Genetics



RD Connect



International Cancer Genome Consortium



OPENMINDTED

BioCreAtive

ASSET EU VIIFP

Spanish MINECO "gene sets"



www.cnio.es

Looking for students, postdocs and bioinformaticians ...




Bioinformatics Unit



MPIMG


Babraham



Juliane Perner

Martin Vingron

Ho-Ryun Chung



Biola-Maria Javierre

Peter Fraser

Mikhail Spivakov



Translational Bioinformatics




Enrique Carrillo

David Juan

Simone Marsili

Daniel Rico

Vera Pancaldi



Spanish National Bioinformatics Institute



Alfons_Valencia

